AstraZeneca taps Owlstone’s breath biopsy device to identify asthma, COPD biomarkers

AstraZeneca taps Owlstone’s breath biopsy device to identify asthma, COPD biomarkers

Submitted by admin on April 9, 2018 - 9:04am
Source: 
Drug Delivery Business News
News Tags: 
AstraZeneca
Owlstone Medical
diagnostics
asthma
COPD
Headline: 
AstraZeneca taps Owlstone’s breath biopsy device to identify asthma, COPD biomarkers
snippet: 

Pharmaceutical giant AstraZeneca (NYSE:AZN) inked a deal with Owlstone Medical to use the diagnostics company’s breath biopsy device to identify biomarkers for asthma and chronic obstructive pulmonary disease, the companies announced today.

Do Not Allow Advertisers to Use My Personal information